Loading
4-1BB is a switch on activated T cells that makes them live longer and kill better. Rather than press it everywhere, new bispecific antibodies press it only on T cells that are already touching a tumour cell marked by PD-L1 or HER2. This dossier gathers the 2 products (0 approved), 3 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Both corpus agents cluster 4-1BB only where the other arm has bound a tumour antigen (PD-L1 or HER2), so costimulation is confined to T cells in contact with the tumour rather than delivered systemically.
| Modality | Phase 3 | Phase 2 |
|---|---|---|
| Bispecific antibody 1 | - | |
| fusion protein 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | - | ||
| 2 | Active | A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | - | ||
| 2 | Withdrawn | A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination Pembrolizumab Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD137" OR ABSTRACT:"CD137" OR TITLE:"4-1BB, TNFRSF9" OR ABSTRACT:"4-1BB, TNFRSF9" OR TITLE:"TNFRSF9" OR ABSTRACT:"TNFRSF9" OR TITLE:"4-1BB" OR ABSTRACT:"4-1BB" OR TITLE:"ILA" OR ABSTRACT:"ILA" OR TITLE:"TNF receptor superfamily member 9" OR ABSTRACT:"TNF receptor superfamily member 9") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD137 (4-1BB, TNFRSF9), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd137.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd137.json. Licence CC BY-NC 4.0.